

IMMUNOASSAY OF PIVKA-II

Ins
AI
5

Case	Age	Sex	Duration	Location	Findings	Comments
1	10	M	10 days	Left eye	Small, dark, pigmented lesion	Benign
2	12	F	2 weeks	Right eye	Small, dark, pigmented lesion	Benign
3	15	M	3 weeks	Left eye	Small, dark, pigmented lesion	Benign
4	18	F	4 weeks	Right eye	Small, dark, pigmented lesion	Benign
5	20	M	5 weeks	Left eye	Small, dark, pigmented lesion	Benign
6	22	F	6 weeks	Right eye	Small, dark, pigmented lesion	Benign
7	25	M	7 weeks	Left eye	Small, dark, pigmented lesion	Benign
8	28	F	8 weeks	Right eye	Small, dark, pigmented lesion	Benign
9	30	M	9 weeks	Left eye	Small, dark, pigmented lesion	Benign
10	32	F	10 weeks	Right eye	Small, dark, pigmented lesion	Benign
11	35	M	11 weeks	Left eye	Small, dark, pigmented lesion	Benign
12	38	F	12 weeks	Right eye	Small, dark, pigmented lesion	Benign
13	40	M	13 weeks	Left eye	Small, dark, pigmented lesion	Benign
14	42	F	14 weeks	Right eye	Small, dark, pigmented lesion	Benign
15	45	M	15 weeks	Left eye	Small, dark, pigmented lesion	Benign
16	48	F	16 weeks	Right eye	Small, dark, pigmented lesion	Benign
17	50	M	17 weeks	Left eye	Small, dark, pigmented lesion	Benign
18	52	F	18 weeks	Right eye	Small, dark, pigmented lesion	Benign
19	55	M	19 weeks	Left eye	Small, dark, pigmented lesion	Benign
20	58	F	20 weeks	Right eye	Small, dark, pigmented lesion	Benign
21	60	M	21 weeks	Left eye	Small, dark, pigmented lesion	Benign
22	62	F	22 weeks	Right eye	Small, dark, pigmented lesion	Benign
23	65	M	23 weeks	Left eye	Small, dark, pigmented lesion	Benign
24	68	F	24 weeks	Right eye	Small, dark, pigmented lesion	Benign
25	70	M	25 weeks	Left eye	Small, dark, pigmented lesion	Benign
26	72	F	26 weeks	Right eye	Small, dark, pigmented lesion	Benign
27	75	M	27 weeks	Left eye	Small, dark, pigmented lesion	Benign
28	78	F	28 weeks	Right eye	Small, dark, pigmented lesion	Benign
29	80	M	29 weeks	Left eye	Small, dark, pigmented lesion	Benign
30	82	F	30 weeks	Right eye	Small, dark, pigmented lesion	Benign
31	85	M	31 weeks	Left eye	Small, dark, pigmented lesion	Benign
32	88	F	32 weeks	Right eye	Small, dark, pigmented lesion	Benign
33	90	M	33 weeks	Left eye	Small, dark, pigmented lesion	Benign
34	92	F	34 weeks	Right eye	Small, dark, pigmented lesion	Benign
35	95	M	35 weeks	Left eye	Small, dark, pigmented lesion	Benign
36	98	F	36 weeks	Right eye	Small, dark, pigmented lesion	Benign
37	100	M	37 weeks	Left eye	Small, dark, pigmented lesion	Benign
38	102	F	38 weeks	Right eye	Small, dark, pigmented lesion	Benign
39	105	M	39 weeks	Left eye	Small, dark, pigmented lesion	Benign
40	108	F	40 weeks	Right eye	Small, dark, pigmented lesion	Benign
41	110	M	41 weeks	Left eye	Small, dark, pigmented lesion	Benign
42	112	F	42 weeks	Right eye	Small, dark, pigmented lesion	Benign
43	115	M	43 weeks	Left eye	Small, dark, pigmented lesion	Benign
44	118	F	44 weeks	Right eye	Small, dark, pigmented lesion	Benign
45	120	M	45 weeks	Left eye	Small, dark, pigmented lesion	Benign
46	122	F	46 weeks	Right eye	Small, dark, pigmented lesion	Benign
47	125	M	47 weeks	Left eye	Small, dark, pigmented lesion	Benign
48	128	F	48 weeks	Right eye	Small, dark, pigmented lesion	Benign
49	130	M	49 weeks	Left eye	Small, dark, pigmented lesion	Benign
50	132	F	50 weeks	Right eye	Small, dark, pigmented lesion	Benign
51	135	M	51 weeks	Left eye	Small, dark, pigmented lesion	Benign
52	138	F	52 weeks	Right eye	Small, dark, pigmented lesion	Benign
53	140	M	53 weeks	Left eye	Small, dark, pigmented lesion	Benign
54	142	F	54 weeks	Right eye	Small, dark, pigmented lesion	Benign
55	145	M	55 weeks	Left eye	Small, dark, pigmented lesion	Benign
56	148	F	56 weeks	Right eye	Small, dark, pigmented lesion	Benign
57	150	M	57 weeks	Left eye	Small, dark, pigmented lesion	Benign
58	152	F	58 weeks	Right eye	Small, dark, pigmented lesion	Benign
59	155	M	59 weeks	Left eye	Small, dark, pigmented lesion	Benign
60	158	F	60 weeks	Right eye	Small, dark, pigmented lesion	Benign

15 Induced by Vitamin K Absence or Antagonist-II) is measured
widely in clinical examination laboratories as a hepatic cell tumor
detecting marker which specifically increases in hepatic cell
cancer patients. Generally, magnetic beads, glass beads, plastic
plates, latexes or the like on which PIVKA-II specific monoclonal
20 or polyclonal antibodies are adsorbed are subjected to a first
reaction with serum or plasma, then after being washed for B/F
separation, a second reaction where human prothrombin specific
polyclonal or monoclonal antibodies labeled with an enzyme, a
fluorescent material, a radioisotope, an Ru complex or the like are
25 added is carried out, and further after being washed for B/F

ATTACHMENT A

separation, absorbance or luminescence of the enzyme, the fluorescent material, the radioisotope or the Ru bound to an immune complex formed through the antigen-antibody reaction being measured to determine PIVKA-II in the serum or the plasma.

Heretofore, PIVKA-II has been measured by an enzyme immunoassay (EIA), but the EIA is poor in sensitivity with a low positive rate for a relatively small hepatoma, so that an electrochemiluminescence immunoassay (ECLIA) where an antigen or an antibody is labeled with an Ru complex has been recently developed for further highly sensitive measurement. The application of the electrochemiluminescence immunoassay led successfully to higher sensitivity in the PIVKA-II measurement. To realize higher sensitivity not only in the ECLIA but also in an enzyme immunoassay, a chemiluminescence assay, a radioisotope assay, latex turbidimetry or the like, the influence of an unspecific reaction in a sample should be taken into consideration.

In the process of studies for eliminating the influence of the unspecific reaction in a sample in the PIVKA-II measurement, it has been found that sensitivity and specificity of the measurement could be improved by adding to reagents thrombin and/or an antibody reacting highly sensitively with human fibrin-like related substances. As the substances attributable to such an unspecific reaction in the sample, attention was directed first to fibrin or its related substances in the sample and second to

thrombin bound to fibrin or its related substances. In particular, when a polyclonal antibody is used as an anti-human prothrombin antibody for a second antibody or a labeled antibody, it may be subject to the interference of these unspecific reaction substances to cause positive errors in measurement of PIVKA-II. It is reported that the protein structure of prothrombin is composed of an F₁ fragment, an F₂ fragment and thrombin. The labeled antibody used for measurement of PIVKA-II may be not only an anti-prothrombin antibody but also an anti-F₁ antibody, an anti-F₂ antibody, or an anti-(F₁ + F₂) antibody. However, in consideration of the purity of these antibodies or the similarity of thrombin to the antigen, these antibodies may also react with bound or free thrombin in a sample. Further, in measurement of PIVKA-II, fibrin or its insoluble related substances in a sample, are physically adsorbed onto carriers such as magnetic beads, glass beads, latexes, plastic plates or the like to give rise to the phenomenon of positive errors in the measurement.

In order to prevent the interference attributable to the fibrin-like related substances and the interference attributable to thrombin, antibodies reacting with the human fibrin-like related substances, for example, anti-fibrinogen or anti-fibrin antibodies and/or thrombin are added to reagents, thereby succeeding in accurately measuring a very small amount of PIVKA-II while effectively inhibiting the nonspecific reaction, leading to the achievement of the present invention.

5 human fibrin-like related substances.

10 of adding to reagents thrombin and/or an antibody reacting with human fibrin-like related substances, and measuring PIVKA-II in serum or plasma.

15 which may be heated or unheated.

20 reacting with not only fibrinogen or fibrin but also fibrin-like
related substances such as FDP, fibrinopeptide A or fibrinopeptide
B. As the thrombin, there are used purified preparations of those
derived from human beings or animals such as cows, pigs, sheep,
horses, rabbits and chickens. Further, the use of a wide variety
25 of thrombin-containing animal serums such as bovine serum, sheep

serum, porcine serum, horse serum, chicken serum and rabbit serum derived from animals different from species of animals immunized for obtaining the labeled antibodies or second antibodies may lead to reaction inhibition of anti-thrombin antibodies occurring as impurities in the labeled antibodies.

As the labeled antibodies or second antibodies used in the present invention, it is possible to use not only human polyclonal antibodies against prothrombin, F_1 , F_2 , or $F_1 + F_2$, but also human monoclonal antibodies against prothrombin, F_1 , F_2 , or $F_1 + F_2$. Here, F_1 and F_2 are peptides constituting prothrombin. Polyclonal or monoclonal antibodies prepared by immunization with synthetic peptides having the antigenicity of prothrombin can also be used.

The Examples of the present specification show application to electrochemiluminescence immunoassay. The present invention is also useful in trial of chemiluminescence assay, radioisotope assay or the like to achieve higher sensitivity. In the present invention, antibodies such as anti-fibrinogen antibody and anti-fibrin antibody reacting with fibrin-like related substances such as fibrinogen, fibrin, FDP, fibrinopeptide A and fibrinopeptide B are preferably obtained by immunization with human-derived fibrin-like related substances, but antibodies obtained by immunization with fibrin-like related substances such as animal-derived fibrinogen, fibrin or the like, and cross-reacting with human-derived fibrin-like related substances can also be used.

The antibodies such as anti-fibrinogen or anti-fibrin antibodies specific to fibrin-like related substances are preferably added to a reaction solution in the first reaction of the 2-step sandwich method. On the other hand, thrombin is preferably added to the labeled antibody solution or the second antibody solution in the second reaction, the adding amount thereof being preferably 1 to 50 NIH/ml. Those antibodies specific to fibrin-like related substances such as anti-fibrinogen or anti-fibrin antibodies, a purified thrombin, and an animal serum containing thrombin may be used singly or jointly as the occasion demands.

The animal serums containing thrombin, such as bovine serum, sheep serum, porcine serum, horse serum, chicken serum and rabbit serum derived from animals different from species of animals immunized for obtaining the labeled antibodies or second antibodies may be preferably added in an amount of 1 to 20 %. These animal serums derived from different species of animals may be blended, when necessary, with animal serums derived from the same animals as species of animals immunized for obtaining the labeled antibody or second antibody.

If the enzyme activity of thrombin is strong when adding thrombin to reagents, the immune reaction may be adversely affected, while if animal serums are added to those reagents containing the labeled antibodies or second antibodies, the stability of the reagents may be adversely affected, and therefore, a protease inhibitor for inhibiting the enzyme activity of thrombin

is preferably added to the reagents to which thrombin or animal serums are added.

As the protease inhibitor, it is possible to use inhibitors, mentioned on page 452 in "Rinsho Koso Handbook (Clinical Enzyme Handbook)" (1st ed., edited by Kitamura, Baba et al. and issued by Kodansha Scientific Co., on September 10, 1982), that is, plasma proteinous inhibitors, hirudine, benzamidine and synthetic inhibitor such as PMSF (phenylmethanesulfonyl fluoride), NPGb and or the like. However, these inhibitors are not sufficient for inhibiting the enzyme activity of thrombin, so it has been found that the enzyme activity is significantly reduced without losing its antigenicity even when a purified preparation of thrombin is subjected to heat treatment, e.g., at about 40 to 65 °C.

A commercial purified preparation of thrombin is to be stored primarily in a refrigerated or frozen form and not to be exposed to a high temperature. The heating temperature for thrombin used in the present invention is 30 to 70 °C, particularly preferably 40 to 60 °C, so that the heating time can be reduced to 15 to 60 minutes. As a matter of course, this heating is aimed at inactivating the enzyme activity of thrombin, and hence insofar as the enzyme can be inactivated without losing its antigenicity, the heating temperature and heating time are not limited to the above ranges.

If the animal serum derived from animals of species different from animals immunized for the labeled antibody is

previously heated for use as thrombin, the heating temperature is preferably 50 to 65 °C and the heating time is preferably 15 to 60 minutes. However, the heating time and heating temperature, needless to say, can be regulated without particular limitation in case of need. Further, the animal serum can be used without heating, if necessary.

Best Mode for Carrying out the Invention:

Hereinafter, the present invention is described by reference to the Examples, but these Examples are shown for illustrative purposes only and are not construed as restrictive.

Example 1 (an example of measurement by an electrochemiluminescence immunoassay in an automatic analyzer Picolumi 8220)

After 50 µl of a sample was added to 150 µl of a reaction solution, 25 µl of magnetic beads having anti-PIVKA-II monoclonal antibody immobilized thereon were added thereto. After they were reacted at 30 °C for 9 minutes, 350 µl of a Picolumi BF washing solution (10 mM Tris buffer) was added, and the magnetic beads trapped by a magnet were washed 3 times. To the magnetic beads thus subjected to the first reaction was added 200 µl of Ru-labeled antibody solution containing 1 µg/ml of a Ru-labeled anti-human prothrombin antibody (derived from rabbit), and these were allowed to react at 30 °C for 9 minutes. Likewise, the magnetic beads trapped by a magnet were washed 3 times with the

Picolumi BF washing solution. After addition of 300 μ l of a Picolumi luminescent electrolytic solution containing 0.1 M tripropyl amine, the magnetic beads were sent to the surface of an electrode and the luminescence of Ru bound to the magnetic beads was measured, the amount of PIVKA-II in the sample being determined.

Reagent composition

Reaction solution: 50 mM Tris buffer (pH 7.8), 0.150 M NaCl, 0.01 % Tween 20, 0.1 % NaN_3 , 5 % rabbit serum (heated).

10 Ru-labeled antibody solution: 50 mM Tris buffer (pH 7.8), 0.150 M NaCl, 0.01 % Tween 20, 0.1 % NaN_3 , 1 mM PMSF, 1 μ g/ml Ru-labeled anti-human prothrombin antibody (derived from rabbit), 5 % rabbit serum (heated).

(Preparation of solid-phase magnetic beads having anti-PIVKA-II monoclonal antibody)

15 1 ml of 30 mg/ml magnetic beads (4.5 microns) was put into a test tube and trapped with a magnet, and after the supernatant was discarded, 1 ml of 0.5 mg/ml anti-PIVKA-II monoclonal antibody (in 150 mM phosphate buffer, pH 7.8) was added to the magnetic beads, and these were allowed to react at room temperature for 1 day under stirring. After the magnetic beads were washed, 2 ml of 1 % BSA-Phosphate buffer was added thereto, and the magnetic beads were blocked for 1 day under stirring at room temperature. In case of use, the magnetic beads were diluted to 1 mg/ml with the 1 % BSA-Phosphate buffer.

(Preparation of Ru-labeled anti-human prothrombin antibody)

68 μ l of Ru-complex compound of ruthenium-tri-dipyridyl modified with a succinimide group was added to 1 ml of 1 mg/ml anti-human prothrombin antibody immunized with rabbits, and these were allowed to react for 30 minutes under stirring at room temperature, and then the reaction was terminated by adding 50 μ l of 2 M glycine, and further the sample was allowed to react for 10 minutes under stirring at room temperature. Finally, the sample was applied onto Sephadex G-25 (previously equilibrated with 10 mM phosphate buffer), and fractions of Ru-bound protein were collected. The Ru-labeled anti-human prothrombin antibody thus obtained was diluted to 1 μ g/ml in case of use.

180 μ g/ml of anti-human fibrinogen antibody (derived from rabbit) was added to each reaction solution, a control solution without the anti-human fibrinogen antibody (derived from rabbit) and 8 human serums being used to compare their specificity. Each serum was measured at $n = 3$, and the results are shown in Table 1. Those reagents with the anti-human fibrinogen antibody (derived from rabbit) show low dispersion in measured values and the absence of unspecific reaction.

Table 1

								mAU/ml
	Control			C.V.	Addition of anti-fibrinogen antibody (180µg/ml)			C.V.
1	56	38	98	50.0%	26	23	24	6.3%
2	47	45	35	15.2%	27	27	28	2.1%
3	37	35	30	10.6%	26	33	29	12.0%
4	55	21	25	55.2%	20	22	19	7.5%
5	27	37	44	23.7%	15	19	15	14.1%
6	21	23	26	10.8%	19	19	20	3.0%
7	22	31	22	20.8%	21	20	18	7.8%
8	30	24	24	13.3%	24	24	24	0.0%

Example 2

5 In this example, the same reagent composition in Example 1 was used except that 10 NIH/ml of a purified preparation of bovine thrombin or human thrombin was added to the Ru-labeled antibody solution. This sample showing particularly highly unspecific reactions was selected and measured simultaneously for PIVKA-II at n = 10. The results of this sample and a control sample in which neither the bovine thrombin nor the human thrombin was added are shown in Table 2.

15 When the purified preparation of bovine or human thrombin was added to the reagent, the specificity of the sample was improved as compared with the control sample. This sample serum was centrifuged at 3000 rpm for 10 minutes and an obtained supernatant thereof showed 80 mAU/ml.

Example 3

In this example, the same reagent composition in

Example 1 was used except that 180 µg/ml anti-human fibrinogen antibody (derived from rabbit) was added to the reaction solution and 10 NIH/ml bovine thrombin was added to the Ru-labeled antibody solution. This sample showing highly unspecific reaction
 5 was measured simultaneously for PIVKA-II at n = 10. The results of this sample and a control sample to which neither the anti-human fibrinogen antibody (derived from rabbit) nor the bovine thrombin was added are shown in Table 2 with the results in Example 2. Addition of both the anti-human fibrinogen
 10 antibody (derived from rabbit) and bovine thrombin leads to an increase in specificity of PIVKA-II much more in comparison with addition of bovine thrombin alone.

Table 2

15

	Control	Addition of human thrombin	Addition of bovine thrombin	Use of both bovine thrombin and anti-human fibrinogen antibody
1	365	121	99	97
2	219	83	145	80
3	158	83	112	79
4	209	88	107	89
5	202	95	119	72
6	150	154	104	79
7	247	84	110	80
8	133	110	103	82
9	166	121	94	85
10	245	92	103	100
Mean	209.4	103.1	109.6	84.3

Example 4

500 NIH of a purified preparation of bovine thrombin was added to 1 ml of 50 mM Tris buffer (0.15 M NaCl, pH 7.8) and heated at 50 °C for 30 minutes in a thermostatic water bath. In this example, the same reagent composition in Example 1 was used except that 180 µg/ml anti-human fibrinogen antibody (derived from rabbit) was added to the reaction solution and the heat-treated purified preparation of bovine thrombin was added at a concentration of 5 NIH/ml to the Ru-labeled antibody solution. Using this sample with a high unspecific reaction, PIVKA-II was measured. The results of this sample and a control sample to which neither the anti-human fibrinogen antibody (derived from rabbit) nor the heated bovine thrombin was added are shown in Table 3. As is evident from the results in Table 3, the inhibitory effect of the sample solutions in this example against the unspecific reaction was exhibited similarly in Example 3. The enzyme activity of this heated thrombin, as measured using Chromozyme TH (Boehringer), was reduced to 1/5 compared with that of the unheated thrombin.

Table 3

		mAU/ml
	Control	Use of both heated bovine thrombin and anti-human fibrinogen antibody
1	133	105
2	154	87
3	152	92
4	219	132
5	150	52
6	100	87
7	137	98
8	125	90
9	162	89
10	127	86
Mean	145.9	91.8

Examples 5 and 6

5 In this example, the same reagent composition in Example 1 was used except that 5 % unheated rabbit serum (a control where the final concentration of the rabbit serum was 10 %), 5 % unheated horse serum (Example 5), or 5 % unheated sheep serum (Example 6) was added to Ru-labeled antibody solution, respectively. This sample showing highly unspecific reaction was measured for its inhibitory effect against the unspecific reaction, and the results are shown in Table 4.

Table 4

	Control	Rabbit serum + horse serum	Rabbit serum + sheep serum
1	208	114	114
2	190	104	109
3	196	107	120
4	179	135	136
5	242	170	132
Mean	203	126	122

As compared with the control, the unspecific reaction was inhibited in the sample to which the horse serum or sheep serum was added. This sample showing highly unspecific reaction was centrifuged at 3000 rpm for 10 minutes and an obtained supernatant thereof showed 74 mAU/ml.

10 Capability of Exploitation in Industry:

As described above, according to the present invention, PIVKA-II in serum or plasma can be measured specifically and highly sensitively by adding to reagents thrombin and/or an antibody reacting with human fibrin-like related substances.